290 related articles for article (PubMed ID: 35757399)
1. Construction of a Tumor Immune Microenvironment-Related Prognostic Model in BRAF-Mutated Papillary Thyroid Cancer.
Xia Y; Jiang X; Huang Y; Liu Q; Huang Y; Zhang B; Mei Z; Xu D; Shi Y; Tu W
Front Endocrinol (Lausanne); 2022; 13():895428. PubMed ID: 35757399
[TBL] [Abstract][Full Text] [Related]
2. STRA6 regulates tumor immune microenvironment and is a prognostic marker in BRAF-mutant papillary thyroid carcinoma.
He W; Sun Y; Ge J; Wang X; Lin B; Yu S; Li Y; Hong S; Xiao H
Front Endocrinol (Lausanne); 2023; 14():1076640. PubMed ID: 36843593
[TBL] [Abstract][Full Text] [Related]
3. Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.
Lin R; Fogarty CE; Ma B; Li H; Ni G; Liu X; Yuan J; Wang T
BMC Genomics; 2021 Jul; 22(1):576. PubMed ID: 34315405
[TBL] [Abstract][Full Text] [Related]
4. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
5. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
Elisei R; Viola D; Torregrossa L; Giannini R; Romei C; Ugolini C; Molinaro E; Agate L; Biagini A; Lupi C; Valerio L; Materazzi G; Miccoli P; Piaggi P; Pinchera A; Vitti P; Basolo F
J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120
[TBL] [Abstract][Full Text] [Related]
6. Different Molecular Phenotypes of Progression in BRAF- and RAS-Like Papillary Thyroid Carcinoma.
Lim J; Lee HS; Park J; Kim KS; Kim SK; Cho YW; Song YS
Endocrinol Metab (Seoul); 2023 Aug; 38(4):445-454. PubMed ID: 37461149
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a nomogram based on stromal score to predict progression-free survival of patients with papillary thyroid carcinoma.
Tang J; Jiang S; Gao Q; Xi X; Gao L; Zhao R; Lai X; Zhang B; Jiang Y
Cancer Med; 2021 Aug; 10(16):5488-5498. PubMed ID: 34240816
[TBL] [Abstract][Full Text] [Related]
8. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
[TBL] [Abstract][Full Text] [Related]
9. Risk and Prognostic Factors for BRAF
Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J
Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194
[TBL] [Abstract][Full Text] [Related]
10. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
Elisei R; Ugolini C; Viola D; Lupi C; Biagini A; Giannini R; Romei C; Miccoli P; Pinchera A; Basolo F
J Clin Endocrinol Metab; 2008 Oct; 93(10):3943-9. PubMed ID: 18682506
[TBL] [Abstract][Full Text] [Related]
11. Construction of a novel cuproptosis-related gene signature for predicting prognosis and estimating tumor immune microenvironment status in papillary thyroid carcinoma.
Wang L; Yao B; Yang J; Tian Z; He J
BMC Cancer; 2022 Nov; 22(1):1131. PubMed ID: 36333684
[TBL] [Abstract][Full Text] [Related]
12. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
13. Identification of iron metabolism-related genes as prognostic indicators for papillary thyroid carcinoma: a retrospective study.
Jin T; Ge L; Chen J; Wang W; Zhang L; Ge M
PeerJ; 2023; 11():e15592. PubMed ID: 37361050
[TBL] [Abstract][Full Text] [Related]
14. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
[TBL] [Abstract][Full Text] [Related]
15. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
[TBL] [Abstract][Full Text] [Related]
16. Prognostic utility of BRAF mutation in papillary thyroid cancer.
Xing M
Mol Cell Endocrinol; 2010 May; 321(1):86-93. PubMed ID: 19883729
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of COX-2 Overexpression in
Parvathareddy SK; Siraj AK; Annaiyappanaidu P; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33327467
[TBL] [Abstract][Full Text] [Related]
18. Correlation between BRAF
Geng J; Wang H; Liu Y; Tai J; Jin Y; Zhang J; He L; Fu L; Qin H; Song Y; Su J; Zhang A; Wen X; Guo Y; Ni X
Sci China Life Sci; 2017 Jul; 60(7):729-738. PubMed ID: 28646474
[TBL] [Abstract][Full Text] [Related]
19. BRAF(V600E) mutation analysis in papillary thyroid carcinoma: is it useful for all patients?
Ito Y; Yoshida H; Kihara M; Kobayashi K; Miya A; Miyauchi A
World J Surg; 2014 Mar; 38(3):679-87. PubMed ID: 24052184
[TBL] [Abstract][Full Text] [Related]
20. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S
Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
